ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
+$0.04 today
- Market cap
- $3.01B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
Volume 3.17M
Average 7.07M
ADMA Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
ADMA Biologics, Inc.NASDAQ: ADMA
Common Stock · Q2 FY2026 · quarter ended Jun 2026
Common stock broadly unchanged from a year ago
Common stock stood at $24K at the end of Q2 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 24K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- +5.2%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24K | +0.0% |
| FY2024 | 2024-12-31 | 24K | +4.3% |
| FY2023 | 2023-12-31 | 23K | +4.5% |
| FY2022 | 2022-12-31 | 22K | +12.4% |
| FY2021 | 2021-12-31 | 19.58K | — |
Common Stock vs competitors
How ADMA compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.0% is the lowest of 4, against a peer median of +2.0%.
- Common stock amounts to 0.0% of total assets for ADMA, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.44B USD | +2.0% | +2.5% | 521.2% | |
| Jun 2026 | €120M EUR | +0.3% | +0.1% | 0.6% | |
| Mar 2026 | $28K USD | +133.3% | +36.5% | 0.0% | |
| Jun 2026 | $24K USD | +0.0% | +2.9% | 0.0% | |
| Peer median (excluding ADMA) | — | +2.0% | +2.5% | 0.6% | |
Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 51.09M | 86.52M | 51.35M | 103.15M | 87.63M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 28.58M | 15.51M | 27.42M | 50M | 158.43M |
| Inventory | 124.72M | 163.28M | 172.91M | 170.24M | 206.47M |
| Other Current Assets | 0 | 5.1M | 5.33M | 8.03M | 13.99M |
| Total Current Assets | 208.73M | 270.4M | 257.01M | 331.41M | 466.51M |
| Property, Plant & Equipment (Net) | 58.2M | 68.75M | 63.47M | 63.34M | 71.71M |
| Goodwill | 3.53M | 3.53M | 3.53M | 3.53M | 3.53M |
| Intangible Assets | 1.73M | 1.01M | 499K | 460K | 632K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 84.28M | 73.26M |
| Other Non-current Assets | 4.07M | 4.77M | 4.67M | 5.66M | 8.6M |
| Total Non-current Assets | 67.52M | 78.06M | 72.17M | 157.27M | 157.73M |
| Total Assets | 276.25M | 348.46M | 329.18M | 488.68M | 624.24M |
| Account Payables | 12.43M | 13.23M | 15.66M | 20.22M | 22.52M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.81M |
| Tax Payables | 0 | 0 | 0 | 3.48M | 0 |
| Deferred Revenue | 142.83K | 143K | 182K | 143K | 0 |
| Other Current Liabilities | 16.05M | 1.8M | 2.37M | 1.85M | 6.82M |
| Total Current Liabilities | 30.38M | 39.27M | 49.81M | 55.54M | 69.54M |
| Long-term Debt | 94.87M | 142.83M | 130.59M | 72.34M | 69.33M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.98M | 1.83M | 1.69M | 1.55M | 1.41M |
| Other Non-current Liabilities | 397.35K | 1.85M | 2.11M | 1.67M | 0 |
| Total Non-current Liabilities | 104.7M | 157.22M | 144.17M | 84.12M | 77.38M |
| Total Liabilities | 135.08M | 196.49M | 193.98M | 139.66M | 146.92M |
| Common Stock | 19.58K | 22K | 23K | 24K | 24K |
| Retained Earnings | (412.11M) | (478.02M) | (506.26M) | (308.58M) | (161.65M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 141.17M | 151.97M | 135.21M | 349.02M | 477.32M |
| Total Debt | 102.92M | 154.44M | 141.42M | 82.12M | 79.89M |
| Net Debt | 51.83M | 67.92M | 90.07M | (21.03M) | (7.75M) |
ADMA Biologics, Inc.
NASDAQ:ADMA
Intrinsic Alpha fair value
Locked
Current Price
$13.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.